Press Release


5th April 2022 - Upperton Pharma Solutions launches nasal delivery development platform

Nottingham-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions, has launched a unique nasal delivery development platform, UpperNose™, to make it easier and faster for small and mid-sized innovators to access the knowledge and capabilities necessary for the successful development of nasal dosage formulations.

Drug developers seeking to evaluate options for the successful delivery of either an active pharmaceutical ingredient (API) or a biologic via the nasal route of administration, can use the UpperNose™ platform to achieve intended delivery objectives. These include local delivery to the nasal membranes, for instance for vaccines, antivirals, or prophylactics, systemic delivery by absorption into the bloodstream, and direct delivery into the brain.

“The delivery of small molecules and biologics via the nose is one of the fastest growing sectors in the drug delivery field,” explains Richard Johnson, Founder and CSO of Upperton Pharma Solutions, “but while the ability to self-administer drugs and vaccines is highly attractive, the specialist knowledge necessary to exploit this delivery route remains scarce”.

“Meeting this demand, the UpperNose platform uses the knowledge and expertise of our experienced scientific team to support the efficient and timely development of molecules in both liquid and dry powder nasal formulations.”

 “The UpperNose technology platform provides our customers with a progressive, data-driven approach to accelerate their nasal drug product development with the selection of the optimal dosage form with the best chances of success in the clinic and beyond,” adds Richard.

 “Working closely with our clients, we will quickly identify the most time and cost effective development programme to facilitate early, smooth passage of our customer’s molecule from early-stage development into clinical trials. Ultimately, the scientific and regulatory data generated by the platform will help get our clients into the clinic with a high degree of confidence, laying the foundation for commercial success without compromising on quality.”

Upperton Pharma Solutions is a specialist CDMO providing formulation, and dosage form development services to the biotechnology and pharmaceutical industries. It offers its clients a complete development service, from early feasibility studies to process optimisation, scale up and clinical trial (GMP / IMP) manufacturing.

To read more about UpperNose™ click here.